Hatem Soliman, MD, discusses the current first-line treatment options for patients with HER2-positive breast cancer. This is a modal window. The Playback API request failed for an unknown reasonError Code: VIDEO_CLOUD_ERR_UNKNOWNTechnical details : Unknown catalog request error....
(2010) First-line treatment of metastatic breast cancer: current strategies and emerging systemic therapies. Community Oncology 7 , 115-123 /Adam, Brufsky. (2010) First-line treatment of metastatic breast cancer: current strategies and emerging systemic therapies. Community Oncology 7 , 115-123 /...
Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer. JCO 29, 1252-1260(2011).
7. Ma F, Yan M, Li W, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, ph...
Topotecan in the First-Line Treatment of Small Cell Lung Cancer Small cell lung cancer (SCLC) is generally sensitive to first-line chemotherapy, but limited disease often recurs and extensive disease is rarely curable. ... Wolf,M. - 《Oncologist》 被引量: 44发表: 2004年 The treatment of ac...
Bevacizumab, a recombinant humanised monoclonal antibody against vascular endothelial growth factor, is approved in Europe as first-line therapy for metast... X Pivot - 《Drugs》 被引量: 115发表: 2007年 Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe? Metastatic breast ca...
[11] LBA15 - MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). ESMO 2022 [12] LBA16 - Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+...
for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of chemotherapy, patient performance status, and patient preferences through a shared decision-making process....
[17]Peter Schmid, et al. Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC) . 2023 ESMO Abstract 379MO.
First-line endocrine therapy for hormone receptor positive and HER-2 negative metastatic breast cancer: A Bayesian network meta-analysis fundamental treatment option for hormone receptor-positive (HR+) and receptor tyrosine-protein kinase erbB-2-negative (HER2-) metastatic breast cancer (mBC)... YC...